AbbVie, Inc. (ABBV)

86.23
NYSE
Prev Close 85.91
Day Low/High 85.46 / 86.86
52 Wk Low/High 62.55 / 101.28
Exchange NYSE
Shares Outstanding 1764.83B
Market Cap 151.62B
P/E Ratio 74.06
Div & Yield N.A. (N.A)

Biowreck (Part Deux)

The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.

Biotechs, Autos Look Good in This Selloff

Biotechs, Autos Look Good in This Selloff

Put cash to work in large-caps that have become cheap in the current market.

Why I'm Adding to My Biotech Positions

Why I'm Adding to My Biotech Positions

I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.

Abbvie upgraded at Citi

My Take on Stock Buybacks

One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...

AbbVie Looks Like It's Bottoming Out

AbbVie Looks Like It's Bottoming Out

Charts show the drug firm has a good entry point approaching.

Anchor Your Portfolio With a Sturdy Front 5

Anchor Your Portfolio With a Sturdy Front 5

Just as the offensive line is vital to a team's success, so are consistent performers in a portfolio.

Morgan Stanley Healthcare Conf.

AbbVie Has More Downside to Go

AbbVie Has More Downside to Go

The stock has shown awful relative strength.

Another Rally Fades Into the Sunset

Another Rally Fades Into the Sunset

China, and Fed rate hike uncertainty, continue to drive volatility.

Let's Go Bottom-Fishing!

Let's Go Bottom-Fishing!

The next couple of sessions offer an opportunity to nibble at four names with lower entry points.

Be Ready If This Is Just a One-Day Rally

Be Ready If This Is Just a One-Day Rally

Have your shopping list of stocks handy in case markets tank again.

Keep Calm and Shop for Bargains

Keep Calm and Shop for Bargains

It could be time to deploy some of your dry powder.

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.

Price Isn't a Problem for Gilead Sciences

Price Isn't a Problem for Gilead Sciences

Drugmaker has one of the best showings of earnings season.

Price Isn't a Problem for Gilead Sciences

Price Isn't a Problem for Gilead Sciences

Drugmaker has one of the best showings of earnings season.

Avoid Gilead Shares for Now

Avoid Gilead Shares for Now

Competition and lower earnings cloud its future.

What to Watch Friday: American Airlines Earnings, New Home Sales

What to Watch Friday: American Airlines Earnings, New Home Sales

For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).

How to Navigate This Week's Earnings Minefield

Don't make a learning week a gambling week.

What to Watch in the Week Ahead: Apple Earnings, Housing Data

What to Watch in the Week Ahead: Apple Earnings, Housing Data

For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.

Looking for the Next Receptos Is Plain Stupid Right Now

Looking for the Next Receptos Is Plain Stupid Right Now

These stocks will be up so high today, that many fans will say "no thanks."

The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding

The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding

This market is almost entirely special situation.

3 Dividend Hikes This Week You Should Know About

3 Dividend Hikes This Week You Should Know About

Duke Energy's recent increase puts its payout at the high end of the industry range.

'GILDed Age' Is Over for Gilead Shares

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

AbbVie Is Knocking on the Door Again

AbbVie Is Knocking on the Door Again

The ABBV chart looks constructive, with solid volume and bullish indicators.

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas

Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.